Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 6Sarcoma 3Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Whole-Brain Radiotherapy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Locally Advanced Thyroid Gland Carcinoma 1Leiomyosarcoma 1Kidney Neoplasms 1Hyperthermia 1HER2-Negative Breast Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 2Carboplatin 2tislelizumab 1aumolertinib 1anlotinib 1aflutinib 1Platinum Compounds 1Pemetrexed 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Non-small Cell Lung Cancer × anlotinib × Clear all
NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡